Paradigm Raises A$9 Million
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- PAR reports pain reduction in oa patients
- Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
- Appendix 4E and 2018 Annual Report
- PAR achieves 60 per cent reduction in osteoarthritis pain
- PAR achieves 100 per cent recruitment in Phase 2b OA Trial
Later from Paradigm Biopharmaceuticals
- Paradigms Updated Corporate Presentation
- Paradigm Agreement With USA Past Players Network
- PAR reports pain reduction in 145 people with osteoarthritis
- Paradigm receives $2.32m R&D tax incentive refund
- Paradigm in-licenses treatment for rare joint disease
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals